Popular Pre-Market Trades in U.S. Stocks

BigBear.ai is up 7.02% in pre-market trading, possibly related to the recent optimistic sentiment in the AI sector. Recent news about BigBear.ai indicates that the company's stock price has risen over 150% in the past year, despite a decline this year. The market's optimism about AI may have driven the short-term increase in stock price. However, with the U.S. government's scrutiny of AI-related spending, BigBear.ai's business growth may face challenges. Additionally, the company's Chief Financial Officer Julie Peffer reported the disposal of common stock, which may have raised market concerns about the company's internal dynamics. Nevertheless, the market's optimism about the AI sector may still be the main driving factor behind the stock price increase. Analysts rate BigBear.ai as a moderate buy, but it is not listed as a top recommended stock. The market's optimism about AI may have driven the short-term increase in stock price. However, analysts point out that BigBear.ai has yet to demonstrate a sustainable business model, and investors should carefully consider its long-term investment value.

Top Gainers in U.S. Pre-Market Trading

Septerna is up 69.24% in pre-market trading, possibly due to a collaboration agreement with Novo Nordisk, expected to yield $2.2 billion. Septerna has entered into a global collaboration and licensing agreement with Novo Nordisk aimed at developing oral small molecule drugs for obesity and other cardiovascular metabolic diseases. This collaboration combines Novo Nordisk's expertise in the field with Septerna's specialization in G protein-coupled receptor drug discovery. Under the agreement, Septerna will receive over $220 million in upfront and near-term milestone payments, with total revenues potentially reaching $2.2 billion. Novo Nordisk will bear all R&D costs, and Septerna retains the option to participate in global profit sharing for one project. This agreement is expected to be completed in the second quarter of 2025, subject to customary conditions. Following this announcement, the market has a positive outlook on Septerna's future development, leading to a significant pre-market increase in its stock price.

Quoin Pharmaceuticals is up 64.15% in pre-market trading, possibly due to positive clinical data for its QRX003 drug and optimistic ratings from analysts. The significant rise in Quoin Pharmaceuticals' stock price is primarily attributed to positive clinical data for its QRX003 drug in pediatric exfoliative skin syndrome studies. According to the latest reports, patients showed significant improvement in skin condition after 12 weeks, with no adverse events reported. This news has bolstered market confidence in the company's future development, driving the stock price up.

Additionally, analysts have shown an optimistic attitude toward Quoin Pharmaceuticals' ratings. According to the latest analysis, the market's 12-month target price for the company is $60.20, with no analysts giving a "hold" or "sell" rating. This positive market sentiment further supports the rise in stock price Analysts' ratings for Quoin Pharmaceuticals show strong optimism. According to the latest analysis, the market's 12-month target price for the company is $60.20, with no analysts giving a "hold" or "sell" rating.

This positive market sentiment may be due to the company's favorable results in clinical trials and the market's confidence in its future growth potential. Analysts' optimistic ratings and target prices reflect their confidence in the company's future performance, which may further attract investor interest and drive up the stock price.

Innovative Eyewear rose 46.97% in pre-market trading, possibly related to its release of financial results for the first quarter of 2025 and a new product line. Innovative Eyewear's stock price surged 46.97% in pre-market trading, likely linked to the company's recent release of its unaudited financial results for the first quarter of 2025. The release of financial reports typically impacts investor confidence and market expectations, especially when results exceed expectations. Additionally, the company launched a new Reebok product line aimed at the active lifestyle market, and the Lucyd Armor smart safety glasses continue to achieve success. The expansion of these product lines may have bolstered market confidence in the company's future growth. The company has also expanded its sales team to support the launch and expansion of these product lines, indicating that it is actively seeking to grow its market share. These factors may collectively drive the stock price increase